Annovis Bio to Present at the 2020 BIO Investor Forum
12 oct. 2020 16h05 HE
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease
29 sept. 2020 06h45 HE
|
Annovis Bio Inc.
Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association Study adds further validation that Annovis’ lead compound is the only drug to improve axonal...
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
03 sept. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial
01 sept. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases
20 août 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio CEO Appears on Executive Leaders Radio Program
23 juil. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
20 juil. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
07 juil. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
16 juin 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
09 juin 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., June 09, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...